{"protocolSection": {"identificationModule": {"nctId": "NCT00550953", "orgStudyIdInfo": {"id": "1235.14"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Filtered Trial for Telmisartan 40mg Non-responder", "officialTitle": "Filtered Trial for Telmisartan 40mg Non-responder"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-10"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-26", "studyFirstSubmitQcDate": "2007-10-29", "studyFirstPostDateStruct": {"date": "2007-10-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-11-12", "resultsFirstSubmitQcDate": "2010-01-07", "resultsFirstPostDateStruct": {"date": "2010-02-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-12", "lastUpdatePostDateStruct": {"date": "2014-01-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Boehringer Ingelheim, Study Chair", "oldOrganization": "Boehringer Ingelheim"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary purpose of this study is to:\n\nDemonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT"}, "enrollmentInfo": {"count": 314, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "telmisartan+amlodipine"}, {"type": "DRUG", "name": "telmisartan"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "timeFrame": "Baseline and 8 Weeks"}], "secondaryOutcomes": [{"measure": "Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Adequate response defined that seated trough diastolic blood pressure was \\<90 mmHg or decreased from reference baseline by \\>=10 mmHg at 8 weeks", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Adequate response defined that seated trough systolic blood pressure was \\<140 mmHg or decreased from reference baseline by \\>=20 mmHg at 8 weeks (0 percent at baseline)", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Optimal, normal, high normal blood pressure were defined as follows:\n\n* Optimal: Systolic blood pressure (SBP) \\< 120 mmHg and diastolic blood pressure (DBP) \\< 80 mmHg\n* Normal: SBP \\>= 120 mmHg or DBP \\>= 80 mmHg and SBP \\< 130 mmHg and DBP \\< 85 mmHg\n* High normal: SBP \\>= 130 mmHg or DBP \\>= 85 mmHg and SBP \\< 140 mmHg and DBP \\< 90 mmHg", "timeFrame": "8 weeks"}, {"measure": "Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG", "description": "Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.", "timeFrame": "First administration of randomised treatment to 24 hours post last dose of randomised treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Essential hypertensive patients who satisfying non-responder criteria\n2. Male or Female\n3. Age 20 years or older\n4. Outpatient\n\nExclusion Criteria:\n\n1. Taking four or more anti-hypertensive medications\n2. Secondary hypertension\n3. Mean seated diastolic blood pressure (DBP) \\> 114 mmHg and/or mean seated systolic blood pressure (SBP) \\> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \\< 90 mmHg at Visit 3.\n4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias\n5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV\n6. History of myocardial infarction or cardiac surgery within last 6 months\n7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months\n8. History of unstable angina within last 3 months\n9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve\n10. History of stroke or transient ischemic attack within last 6 months\n11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy\n12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors\n13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs\n14. Hepatic and/or renal dysfunction\n15. Diagnosed biliary atresia or cholestasis\n16. Hyperkalemia\n17. Dehydration\n18. Sodium deficiency\n19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)\n20. Patients who cannot change to the restricted administration and dosage during study period\n21. Pre-menopausal women who meet any one of the following 1 - 3:\n\n    * Pregnant or possibly pregnant (1)\n    * Nursing (2)\n    * Desire to become pregnant during study period (3)\n22. Drug or alcohol dependency\n23. Complication of malignant tumour or a disease requiring immunosuppressants\n24. Compliance of \\< 80% or \\> 120% during the run-in period\n25. Receiving any investigational therapy within 3 months\n26. Judged to be inappropriate by the investigator or the sub-investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1235.14.002 Boehringer Ingelheim Investigational Site", "city": "Chofu, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.64837, "lon": 139.55426}}, {"facility": "1235.14.003 Boehringer Ingelheim Investigational Site", "city": "Musashino, Tokyo", "country": "Japan"}, {"facility": "1235.14.005 Boehringer Ingelheim Investigational Site", "city": "Nishi-ku, Hiroshima, Hiroshima", "country": "Japan"}, {"facility": "1235.14.004 Boehringer Ingelheim Investigational Site", "city": "Osaka, Osaka", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "1235.14.001 Boehringer Ingelheim Investigational Site", "city": "Shinjuku-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "FG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "156"}, {"groupId": "FG001", "numSubjects": "158"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "150"}, {"groupId": "FG001", "numSubjects": "152"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Not able to visit the site", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "BG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "158"}, {"groupId": "BG002", "value": "314"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.4", "spread": "9.1"}, {"groupId": "BG001", "value": "55.5", "spread": "10.2"}, {"groupId": "BG002", "value": "55.5", "spread": "9.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "77"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "123"}, {"groupId": "BG002", "value": "237"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 Weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.49", "spread": "0.63"}, {"groupId": "OG001", "value": "5.47", "spread": "0.62"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "8.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.41", "ciUpperLimit": "9.63", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.82", "estimateComment": "Difference calculated as telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination minus telmisartan 40 mg monotherapy"}]}, {"type": "SECONDARY", "title": "Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.86", "spread": "0.86"}, {"groupId": "OG001", "value": "6.51", "spread": "0.84"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "78.4"}, {"groupId": "OG001", "value": "46.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "97"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81.2"}, {"groupId": "OG001", "value": "37.1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Adequate response defined that seated trough diastolic blood pressure was \\<90 mmHg or decreased from reference baseline by \\>=10 mmHg at 8 weeks", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "50"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Adequate response defined that seated trough systolic blood pressure was \\<140 mmHg or decreased from reference baseline by \\>=20 mmHg at 8 weeks (0 percent at baseline)", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "89.5"}, {"groupId": "OG001", "value": "58.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Optimal, normal, high normal blood pressure were defined as follows:\n\n* Optimal: Systolic blood pressure (SBP) \\< 120 mmHg and diastolic blood pressure (DBP) \\< 80 mmHg\n* Normal: SBP \\>= 120 mmHg or DBP \\>= 80 mmHg and SBP \\< 130 mmHg and DBP \\< 85 mmHg\n* High normal: SBP \\>= 130 mmHg or DBP \\>= 85 mmHg and SBP \\< 140 mmHg and DBP \\< 90 mmHg", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"title": "Optimal", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.0"}, {"groupId": "OG001", "value": "3.2"}]}]}, {"title": "Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.7"}, {"groupId": "OG001", "value": "17.1"}]}]}, {"title": "High Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "26.1"}, {"groupId": "OG001", "value": "17.1"}]}]}]}, {"type": "SECONDARY", "title": "Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG", "description": "Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.", "populationDescription": "Patients randomised to the double-blind treatment period who took at least one dose either of T40+A5 or T40 during the double-blind treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First administration of randomised treatment to 24 hours post last dose of randomised treatment", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"title": "Arrhythmia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Blood potassium increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Blood pressure increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Eosinophil count increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Orthostatic hypotension", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From drug administration until 24 hours after last drug administration", "eventGroups": [{"id": "EG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning", "seriousNumAffected": 1, "seriousNumAtRisk": 156, "otherNumAffected": 19, "otherNumAtRisk": 156}, {"id": "EG001", "title": "Telmisartan 40 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning", "seriousNumAffected": 0, "seriousNumAtRisk": 158, "otherNumAffected": 16, "otherNumAtRisk": 158}], "seriousEvents": [{"term": "Forearm fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 158}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 158}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract"}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000077333", "term": "Telmisartan"}, {"id": "C000548840", "term": "Telmisartan amlodipine combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M261345", "name": "Telmisartan amlodipine combination", "asFound": "Pressure, pulse", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}